Phenotype switching: tumor cell plasticity as a resistance mechanism and target for therapy

Area of Science:

• Oncology
• Cancer Biology
• Melanoma Research

Background:

• BRAF mutations are common in melanoma, making tumors sensitive to BRAF and MEK inhibitors.
• Therapeutic resistance invariably develops in melanoma patients treated with targeted therapies.
• Phenotype switching, a shift from proliferative to invasive states, is an emerging resistance mechanism.

Purpose of the Study:

• To propose that phenotype switching in melanoma is a form of dynamic tumor cell plasticity.
• To highlight the resemblance between melanoma phenotype switching and epithelial-to-mesenchymal-like transition in cancer stem cells.
• To identify potential therapeutic targets within these plastic tumor cell populations.

Main Methods:

• Comparative analysis of melanoma phenotype switching and epithelial-to-mesenchymal-like transition.
• Characterization of phenotypic and molecular changes associated with therapy resistance.
• Exploration of tumor cell plasticity as a therapeutic vulnerability.

Main Results:

• Phenotype switching enables melanoma cells to resist targeted BRAF and MEK inhibitors.
• Melanoma phenotype switching shares similarities with epithelial-to-mesenchymal-like transition.
• A subset of melanoma cells exhibits dynamic and reversible phenotypic plasticity.

Conclusions:

• Phenotype switching represents a key mechanism of therapeutic resistance in melanoma.
• Tumor cell plasticity is a fundamental characteristic driving melanoma's adaptability.
• Targeting the plasticity of these invasive, resistant melanoma cells offers a promising therapeutic strategy.